IRVINE, Calif.--(EON: Enhanced Online News)--Khang & Khang LLP (the “Firm”) announces that it is investigating claims against Agile Therapeutics, Inc. (“Agile” or the “Company”) (Nasdaq: AGRX) concerning possible violations of federal securities laws.
“deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression.”
If you purchased shares of Agile and want more information, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at email@example.com.
Agile is a pharmaceutical company that develops and markets prescription female contraceptive products.
On January 3, 2017, Agile revealed new information related to its Phase 3 SECURE study assessing Agile's combined hormonal contraceptive patch product, Twirla. The FDA wanted the study after it rejected Agile's initial marketing application in 2013. The Company stated that 2% of study participants suffered "serious adverse events" including "deep vein thrombosis, pulmonary embolism, gallbladder disease, ectopic pregnancy and depression." Furthermore, 51.4% of subjects left the study. When this information was revealed to the public, the value of Agile stock fell sharply causing investors severe harm.
If you have any questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at firstname.lastname@example.org.
This press release may constitute Attorney Advertising in some jurisdictions.